NCT04841811View on ClinicalTrials.gov

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

PHASE3RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Lung Cancer
Interventions
DRUG

Almonertinib

ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy

Trial Locations (1)

510080

RECRUITING

Guangdong Lung cancer institute, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

lead

Guangdong Association of Clinical Trials

OTHER